Erlotinib and bevacizumab combination therapy for afatinib-refractory leptomeningeal carcinomatosis from EGFR-mutated lung cancer

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors remains the main hurdle in treating EGFR-mutated lung cancer. Besides, when leptomeningeal carcinomatosis occurs during treatment, it often leads to treatment failure. We herein report a case of lung adenocarcinoma in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int Cancer Conf J
Autors principals: Abe, Miyuki, Osoegawa, Atsushi, Karashima, Takashi, Takumi, Yohei, Kobayashi, Ryoji, Hashimoto, Takafumi, Miyawaki, Michiyo, Takeuchi, Hideya, Okamoto, Tatsuro, Sugio, Kenji
Format: Artigo
Idioma:Inglês
Publicat: Springer Singapore 2019
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6498220/
https://ncbi.nlm.nih.gov/pubmed/31149553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13691-019-00358-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars